Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (18617)	2/9/1999 6:32:00 PM
From: VLAD	Respond to of 23519

To all: I have a call into Vivus' CFO today. When he calls back I will let everyone know what I find. The things I would like to know are: 1)Is the company considering buying back shares at these cheap prices when they know that they will have $8M cash in possibly less than 1 month? If so must such a decision be immediately announced or are they required to announce it only on their quarterly report? Obviously we would rather they not make such an announcement since it would immediately inflate the stock's price which will lower the number of shares that Vivus can take out of the float. We rather see a quiet accumulation at sub $3.00 prices rather than seeing the stock price pop to $6.00+ because the company announces a stock buy back plan. 2)I have been told by one of my contacts that Vivus will have international sales in Q1 1999 that will be close to the international sales done in Q4 1998. This contradicts what Wilson said in the Q4 1998 conference call. I quote Wilson as saying, "...we now expect to receive the majority of country licenses in the second quarter with product launches in the second and third quarters of 1999. Because Astra built launch inventories in the third and fourth quarters of 1998, we do not expect significant international orders in the first and second quarters of 1999." This statement completely contradicts information I received from Astra last week when they told me that they expect the majority of the EU approvals THIS MONTH (So far we have approval in 6 of the 15 EU countries including England, Sweden, Ireland, Luxembourg, Denmark, and Finland. Wilson's statement is already appearing to be deceptive deception because already 4 out of the remaining 13 EU countries recently licensed MUSE. This means that of the 13 countries that we were waiting for (England and Sweden approved long ago) 4 of them or 31% have already approved licensing and we still have 7 weeks left in Q1 1999. If 3 more EU countries grant licensing for MUSE within the next 7 weeks then Wilson's statement will be proven to be FALSE. Of the remaining 9 countries which have yet to grant licensing, 4 of them are our milestone countries which will each give Vivus a $2M milestone payment. I have been told by a source (reliability unknown) that Wilson purposely made these pessimistic statements to keep Vivus share price low so that Astra/Zeneca could now take an equity position in Vivus stock on the open market because they will eventually want to buy Vivus and all related patents for intraurethral drug delivery. I do not know if this is bs or truth but if it is true it should show up on Edgar once any one investor/institution accumulates over 5% of Vivus stock. So I will ask Vivus if they have any knowledge of these allegations. 3)I finally will try to find out if it is true that Vivus Inc. has as asked the SEC/NASD to investigate market manipulation in Vivus stock. If this is true and proven then brokerages who have been involved in conspired attempts to keep the share price can be sued for millions by anyone who sold their shares because of the severe drop in share price during the summer of 1998.

To: VLAD who wrote (18617)	2/9/1999 6:35:00 PM
From: VLAD	Respond to of 23519

To all!!! Watch CNBC now for the Fen/Phen story. IMO Viagra/Pfizer is next. Get your heads out of your asses lawyers. Here is a golden opportunity for the real attorneys (as opposed to ambulance chasers) to right some wrongs. This media report ought to perhaps give you all a little confidence!

To: VLAD who wrote (18617)	2/9/1999 6:56:00 PM
From: VLAD	Read Replies (2) \| Respond to of 23519

To all!! Watch Entremed tomorrow. biz.yahoo.com Pretty sick how naive the investment community really is. Media hype pops the share price from 12 to over $80.00 in early May 1998 and has been in a trading range between $20 to $35.00 for the past 3+ months. This stock moved on total bs hype regarding 2 proteins that supposedly cut off blood flow to tumors in mice. Some here (myself included) have made some remarks regarding how Vivus has yet to release a single press release about Dr G. Christ's factual and scientific research which has proven that genetic therapy in ED has a very promising future. Injecting Calcium channel pumps (which were produced from human genes) into impotent mouse penile tissue was proven to reverse organic vascular impotence. This is proven fact not hype yet Vivus (I am told because of the past share holder lawsuit) has done not an ounce of media exposure towards this scientific break through. IMO Christ needs to repeat his experiment in primates if the FDA will not approve phase I clinical trials in the very near future. His research will again be proven valid if he can repeat it on monkeys. DaiS, do you know anything about this?